Ms. Suzanne Foster is President of Beckman Coulter Life Sciences. She is a global leader with more than 25 years of experience in the healthcare industry. Previously, she held the positions of President of Cardinal Health’s Health-at-Home and VP General Manager Medtronic Advanced Energy. Earlier in her career, she held various legal and compliance roles focused on health systems and healthcare organizations. Ms. Foster holds a B.A. in Communication from the University of New Hampshire, an M.Ed in Psychology from Notre Dame College, a J.D. from Suffolk University Law School, and a Master of Public Health in Law and Health Policy from Harvard T.H. Chan School of Public Health.
Mr. Cleland is co-founder and principal at Roadmap Capital, and Portfolio Manager of the Roadmap Innovation Funds. Mr. Cleland has a Bachelor of Arts (Honours, 1992/97) from Harvard University and earned his CFA designation in 2001. He was founding portfolio manager at Northern Rivers Capital Management ("Northern Rivers"), where he managed the Northern Rivers Innovation Fund from May of 2001 until Northern Rivers was acquired by BluMont Capital in February of 2010. He co-founded Roadmap Capital Inc. in the summer of 2013. Roadmap and its investors have now invested almost $200M in VC-stage tech companies. Roadmap’s sectors of interest include semiconductors, cybersecurity, material sciences, and medical devices. In addition to serving as a Director on Perimeter's Board, Mr. Cleland is currently a member of the Board of Directors of Ubilite Inc, MMB, Corsa Security, Tornado Spectral Systems, and CHAR Technologies (YES on the TSXV). Prior to Northern Rivers, Mr. Cleland also held various roles at Midland Walwyn Capital and Interward Capital Corporation.
Mr. Aaron Davidson is former CFO and Senior Vice President of Corporate Development of Profound Medical Inc., a medical technology company that is developing real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Before joining Profound, Mr. Davidson served as Co-Head and Managing Director of H.I.G. BioHealth Partners, where he focused on investment opportunities with emerging life sciences companies. Mr. Davidson began his career with Eli Lilly and Company, where he spent a decade in various operating management roles in the United States and Canada, including financial management, business development, strategic planning, market research and general management. While at H.I.G., he led investments in, worked with the management teams of, and represented H.I.G. as a board member of several successful companies, including Alder Biopharmaceuticals (public), Forsight Vision5 (acquired), Gemin X Pharmaceuticals (acquired), HyperBranch Medical Technology (acquired), Intact Vascular, OnTarget Laboratories, Novadaq Technologies (public/acquired), and Salmedix (acquired). Mr. Davidson earned his MBA from Harvard Business School and a bachelor’s degree in finance from McGill University.
Anantha Kancherla is currently Engineering Director at Meta, where he is head of its AI platform. Previously, as VP of Engineering at Lyft, Mr. Kancherla led the Level5 software team responsible for building the self-driving car. Mr. Kancherla previously worked on Windows at Microsoft focusing on DirectX, Graphics and UI. In his former role at Facebook, Mr. Kancherla participated in pioneering the building of mobile software at scale for over a billion users all over the world. Previously, Mr. Kancherla led efforts at Dropbox to launch Dropbox Paper as well as improve core collaboration functionality in Dropbox. Mr. Kancherla obtained a B.Tech in Computer Science and Engineering from the Indian Institute of Technology, and a MS degree in Computer Science from the University of North Carolina Chapel Hill.
Mr. Ian Mortimer has over 20 years of experience in the biotechnology sector. He is currently President and Chief Executive Officer of Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a company developing innovative therapeutics to improve the lives of patients with neurological disorders. Prior to joining Xenon in 2013, Mr. Mortimer spent six years at Tekmira Pharmaceuticals Corporation, now Arbutus Biopharma Corporation (NASDAQ: ABUS), as Executive Vice President and Chief Financial Officer. He led both Xenon’s and Tekmira’s listings on the NASDAQ, in 2014 and 2010 respectively. From 2004 to 2007, Mr. Mortimer was Chief Financial Officer of Inex Pharmaceuticals Corporation. Mr. Mortimer serves on the board of directors of Xenon and is chair of the board of directors for Appili Therapeutics, Inc., a publicly-traded biopharmaceutical company focused on developing treatments for infectious diseases. Mr. Mortimer has an M.B.A. from Queen’s University, a B.Sc. in Microbiology from the University of British Columbia, and is a Chartered Professional Accountant, Certified Management Accountant.
Dr. Vose is an experienced medical device executive and corporate director with a longstanding history in scaling novel surgical technologies, and particularly in breast oncology and reconstruction. Most recently, Dr. Vose served as CEO and Board Director at SIA Health, leading the company through its Series B financing, the commercial growth of DuraSorb®, and acquisition by Integra LifeSciences (NASDAQ: IART). Dr. Vose earned a Masters of Business Administration (MBA) from MIT Sloan School of Management, a Doctor of Medicine (M.D.) from Medical College of Georgia, with general surgery training at Beth Israel Deaconess Medical Center, and a Bachelor of Science (B.S.) in Chemical Engineering from Georgia Institute of Technology.